{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T04:16:34Z","timestamp":1791951394714,"version":"4.3.4"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,1,11]],"date-time":"2022-01-11T00:00:00Z","timestamp":1641859200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p>The significance of Epstein-Barr virus (EBV) infections for the prognosis of patients with peripheral T-cell lymphomas (PTCLs), specifically angioimmunoblastic T-cell lymphoma (AITL) and PTCL not otherwise specified (PTCL-NOS), remains unclear. The Epstein-Barr encoding region can be used to detect EBV in tissue sections by <jats:italic>in situ<\/jats:italic> hybridization (ISH) and by polymerase chain reaction (PCR) assays of peripheral blood samples from patients with PTCLs. This study compared the outcomes patients with AITL or PTCL-NOS for whom the presence of EBV infection was assessed by these two methods.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p>This was a retrospective study of patients newly diagnosed with AITL or PTCL-NOS. All patients were selected from a single transplantation center. EBV-positive lymphomas were detected at the time of diagnosis in tissue sections by ISH or in the blood by PCR.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Out of a cohort of 140 patients with histologically confirmed AITL or PTCL-NOS, 105 were EBV-positive. The 3-year overall survival of patients with EBV-positive TCL was 43.3% compared to 68.6% in patients with EBV-negative TCL (p = .01). Patients who were treated with autologous or allogeneic hematopoietic stem cell transplantation (n = 28 and n = 11, respectively) or chemotherapy alone (n = 66) had 3-year survival rates of 67.0%, 62.3%, and 30.2%, respectively (p &amp;lt;.02). Patients with EBV-positive TCL had a better prognosis after treatment with hematopoietic stem cell transplantation compared to chemotherapy alone, but no difference was seen among patients with EBV-negative TCL.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>EBV infection was shown to negatively affect the clinical outcomes of patients with TCL. Stem cell transplantation has been found to be an effective treatment for EBV-associated lymphomas. Further investigations are warranted to determine the optimal treatment for these patients.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2021.797028","type":"journal-article","created":{"date-parts":[[2022,1,11]],"date-time":"2022-01-11T04:29:15Z","timestamp":1641875355000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":22,"title":["Impact of Epstein-Barr Virus on Peripheral T-Cell Lymphoma Not Otherwise Specified and Angioimmunoblastic T-Cell Lymphoma"],"prefix":"10.3389","volume":"11","author":[{"given":"Tong-Yoon","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gi-June","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young-Woo","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Soo","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung-Hawn","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung-Ah","family":"Yahng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae-Ho","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Eun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byung-Sik","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ki-Seong","family":"Eom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoo-Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seok","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hee-Je","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Ki","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong-Wook","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seok-Goo","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,1,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-020-0247-0","article-title":"Peripheral T Cell Lymphomas: From the Bench to the Clinic","volume":"20","author":"Fiore","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2021.100126","article-title":"Comprehensive Analysis of Peripheral T-Cell and Natural Killer\/T-Cell Lymphoma in Asian Patients: A Multinational, Multicenter, Prospective Registry Study in Asia","volume":"10","author":"Yoon","year":"2021","journal-title":"Lancet Reg Health West Pac"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 Revision of the World Health Organization Classification of Lymphoid Neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.clml.2016.10.001","article-title":"Analysis of Peripheral T-Cell Lymphoma Diagnostic Workup in the United States","volume":"17","author":"Hsi","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.158428","article-title":"Integrative Clinicopathological and Molecular Analyses of Angioimmunoblastic T-Cell Lymphoma and Other Nodal Lymphomas of Follicular Helper T-Cell Origin","volume":"102","author":"Dobay","year":"2017","journal-title":"Haematologica"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.21251","article-title":"Pretreatment Epstein\u2013Barr Virus DNA in Whole Blood Is a Prognostic Marker in Peripheral T-Cell Lymphoma","volume":"8","author":"Kim","year":"2017","journal-title":"Oncotarget"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2017.476","article-title":"The Prognostic Role of Circulating Epstein\u2013Barr Virus DNA Copy Number in Angioimmunoblastic T-Cell Lymphoma Treated With Dose-Adjusted EPOCH","volume":"51","author":"Liang","year":"2019","journal-title":"Cancer Res Treat"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.30566","article-title":"Frequency and Clinical Correlates of Elevated Plasma Epstein\u2013Barr Virus DNA at Diagnosis in Peripheral T-Cell Lymphomas","volume":"140","author":"Haverkos","year":"2017","journal-title":"Int J Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1996.tb01396.x","article-title":"CHOP vs. ProMACE-CytaBOM in the Treatment of Aggressive Non-Hodgkin\u2019s Lymphomas: Long-Term Results of a Multicenter Randomized Trial. (PETHEMA: Spanish Cooperative Group for the Study of Hematological Malignancies Treatment, Spanish Society of Hematology)","volume":"57","author":"Montserrat","year":"1996","journal-title":"Eur J Haematol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2008.00768.x","article-title":"Phase I Study of Dexamethasone, Methotrexate, Ifosfamide, L-Asparaginase, and Etoposide (SMILE) Chemotherapy for Advanced-Stage, Relapsed or Refractory Extranodal Natural Killer (NK)\/T-Cell Lymphoma and Leukemia","volume":"99","author":"Yamaguchi","year":"2008","journal-title":"Cancer Sci"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised Response Criteria for Malignant Lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-018-0289-z","article-title":"Autologous Hematopoietic Cell Transplantation Using Dose-Reduced Intravenous Busulfan, Melphalan, and Thiotepa for High-Risk or Relapsed Lymphomas","volume":"54","author":"Yoon","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"B13","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.clml.2019.03.023","article-title":"Clinical Outcomes of Fludarabine and Melphalan With an 800 cGy Total Body Irradiation Conditioning Regimen in Patients With Refractory or Relapsed Aggressive Non-Hodgkin Lymphoma Undergoing Allogeneic Hematopoietic Stem Cell Transplantation","volume":"19","author":"Jeon","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2019.00141","article-title":"Extranodal Natural Killer\/T-Cell Lymphoma, Nasal Type: Basic Science and Clinical Progress","volume":"7","author":"Harabuchi","year":"2019","journal-title":"Front Pediatr"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-014-1520-3","article-title":"Peripheral T Cell Lymphoma in Asia","volume":"99","author":"Park","year":"2014","journal-title":"Int J Hematol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2008.23.2.185","article-title":"The Spectrum of Epstein\u2013Barr Virus-Associated Lymphoproliferative Disease in Korea: Incidence of Disease Entities by Age Groups","volume":"23","author":"Cho","year":"2008","journal-title":"J Korean Med Sci"},{"key":"B17","doi-asserted-by":"publisher","first-page":"14","DOI":"10.15264\/cpho.2021.28.1.14","article-title":"EBV-Associated Lymphoproliferative Disorders","volume":"28","author":"Ko","year":"2021","journal-title":"Clin Pediatr Hematol Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-536359","article-title":"Gene Expression Signatures Delineate Biological and Prognostic Subgroups in Peripheral T-Cell Lymphoma","volume":"123","author":"Iqbal","year":"2014","journal-title":"Blood"},{"key":"B19","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s12308-014-0230-3","article-title":"When to Use In Situ Hybridization for the Detection of Epstein\u2013Barr Virus: A Review of Epstein\u2013Barr Virus-Associated Lymphomas","volume":"8","author":"Nakatsuka","year":"2015","journal-title":"J Hematopathol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1111\/j.1365-2559.2007.02632.x","article-title":"Distinguishing Angioimmunoblastic T-Cell Lymphoma From Peripheral T-Cell Lymphoma, Unspecified, Using Morphology, Immunophenotype and Molecular Genetics","volume":"50","author":"Attygalle","year":"2007","journal-title":"Histopathology"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-09-454694","article-title":"Plasma Epstein\u2013Barr Virus DNA Predicts Outcome in Advanced Hodgkin Lymphoma: Correlative Analysis From a Large North American Cooperative Group Trial","volume":"121","author":"Kanakry","year":"2013","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1701717","article-title":"Analysis of Plasma Epstein\u2013Barr Virus DNA to Screen for Nasopharyngeal Cancer","volume":"377","author":"Chan","year":"2017","journal-title":"N Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.4505","article-title":"Post-Treatment Plasma EBV-DNA Positivity Predicts Early Relapse and Poor Prognosis for Patients With Extranodal NK\/T Cell Lymphoma in the Era of Asparaginase","volume":"6","author":"Wang","year":"2015","journal-title":"Oncotarget"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-01-067769","article-title":"The Impact of Epstein\u2013Barr Virus Status on Clinical Outcome in Diffuse Large B-Cell Lymphoma","volume":"110","author":"Park","year":"2007","journal-title":"Blood"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00109","article-title":"Epstein Barr Virus Associated B-Cell Lymphomas and Iatrogenic Lymphoproliferative Disorders","volume":"9","author":"Crombie","year":"2019","journal-title":"Front Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-017632","article-title":"Prognostic Significance of Epstein\u2013Barr Virus in Nodal Peripheral T-Cell Lymphoma, Unspecified: A Groupe D\u2019Etude Des Lymphomes De L\u2019adulte (GELA) Study","volume":"108","author":"Dupuis","year":"2006","journal-title":"Blood"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2742","article-title":"Status has Prognostic Implication Among Young Patients With Angioimmunoblastic T-Cell Lymphoma","volume":"9","author":"Eladl","year":"2020","journal-title":"Cancer Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.18.00511","article-title":"Practical Treatment Approach for Angioimmunoblastic T-Cell Lymphoma","volume":"15","author":"Moskowitz","year":"2019","journal-title":"J Oncol Pract"},{"key":"B29","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1038\/s41408-017-0030-y","article-title":"Outcomes of Patients With Peripheral T-Cell Lymphoma in First Complete Remission: Data From Three Tertiary Asian Cancer Centers","volume":"7","author":"Tang","year":"2017","journal-title":"Blood Cancer J"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2011.645818","article-title":"Long-Term Survival in Patients With Peripheral T-Cell Non-Hodgkin Lymphomas After Allogeneic Hematopoietic Stem Cell Transplant","volume":"53","author":"Goldberg","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.40.2719","article-title":"Up-Front Autologous Stem-Cell Transplantation in Peripheral T-Cell Lymphoma: NLG-T-01","volume":"30","author":"d\u2019Amore","year":"2012","journal-title":"J Clin Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx787","article-title":"Role of Up-Front Autologous Stem-Cell Transplantation in Peripheral T-Cell Lymphoma for Patients in Response After Induction: An Analysis of Patients From LYSA Centers","volume":"29","author":"Fossard","year":"2018","journal-title":"Ann Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2014.02.011","article-title":"Human Viral Oncogenesis: A Cancer Hallmarks Analysis","volume":"15","author":"Mesri","year":"2014","journal-title":"Cell Host Microbe"},{"key":"B34","article-title":"Down-Regulation of Intracellular Reactive Oxygen Species Attenuates P-Glycoprotein-Associated Chemoresistance in Epstein\u2013Barr Virus-Positive NK\/T-Cell Lymphoma","volume":"11","author":"Nam","year":"2019","journal-title":"Am J Transl Res"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.05.003","article-title":"Clinical Outcomes and Prognostic Factors of Up-Front Autologous Stem Cell Transplantation in Patients With Extranodal Natural Killer\/T Cell Lymphoma","volume":"21","author":"Yhim","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2015.91","article-title":"Long-Term Outcome of Extranodal NK\/T Cell Lymphoma Patients Treated With Postremission Therapy Using EBV LMP1 and LMP2a-Specific CTLs","volume":"23","author":"Cho","year":"2015","journal-title":"Mol Ther"},{"key":"B37","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1200\/JCO.2013.51.5304","article-title":"Sustained Complete Responses in Patients With Lymphoma Receiving Autologous Cytotoxic T Lymphocytes Targeting Epstein\u2013Barr Virus Latent Membrane Proteins","volume":"32","author":"Bollard","year":"2014","journal-title":"J Clin Oncol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1200\/JCO.2011.39.8495","article-title":"Adoptive Transfer of Epstein\u2013Barr Virus (EBV) Nuclear Antigen 1\u2013Specific T Cells as Treatment for EBV Reactivation and Lymphoproliferative Disorders After Allogeneic Stem-Cell Transplantation","volume":"31","author":"Icheva","year":"2013","journal-title":"J Clin Oncol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s13045-016-0341-7","article-title":"PD-L1 Is Upregulated by EBV-Driven LMP1 Through NF-\u03bab Pathway and Correlates With Poor Prognosis in Natural Killer\/T-Cell Lymphoma","volume":"9","author":"Bi","year":"2016","journal-title":"J Hematol Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-017-1987-x","article-title":"Programmed Death-Ligand 1 and Its Soluble Form Are Highly Expressed in Nasal Natural Killer\/T-Cell Lymphoma: A Potential Rationale for Immunotherapy","volume":"66","author":"Nagato","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-12-756841","article-title":"PD1 Blockade With Pembrolizumab is Highly Effective in Relapsed or Refractory NK\/T-Cell Lymphoma Failing L-Asparaginase","volume":"129","author":"Kwong","year":"2017","journal-title":"Blood"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.797028\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,11]],"date-time":"2022-01-11T04:29:20Z","timestamp":1641875360000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.797028\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,11]]},"references-count":41,"alternative-id":["10.3389\/fonc.2021.797028"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.797028","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,11]]},"article-number":"797028"}}